Zentalis Pharmaceuticals, Inc. (ZNTL)

Market Cap	127.82M
Revenue (ttm)	67.43M
Net Income (ttm)	-165.84M
Shares Out	71.81M
EPS (ttm)	-2.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,001,069
Open	1.860
Previous Close	1.760
Day's Range	1.740 - 2.010
52-Week Range	1.610 - 16.270
Beta	1.75
Analysts	Buy
Price Target	8.53 (+379.21%)
Earnings Date	Mar 26, 2025

About ZNTL

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 3, 2020
• Employees: 124
• Stock Exchange: NASDAQ
• Ticker Symbol: ZNTL
• Website: https://zentalis.com

Analyst Forecast

According to 8 analysts, the average rating for ZNTL stock is "Buy." The 12-month stock price forecast is $8.53, which is an increase of 379.21% from the latest price.

Price Target

$8.53

(379.21% upside)

Analyst Consensus: Buy